0001104659-19-062782.txt : 20191112
0001104659-19-062782.hdr.sgml : 20191112
20191112190241
ACCESSION NUMBER: 0001104659-19-062782
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191108
FILED AS OF DATE: 20191112
DATE AS OF CHANGE: 20191112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bitterman Kevin
CENTRAL INDEX KEY: 0001591747
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 191211325
MAIL ADDRESS:
STREET 1: C/O POLARIS VENTURE PARTNERS
STREET 2: 1000 WINTER STREET, SUITE 3350
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 HARBOR WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
a4.xml
4
X0306
4
2019-11-08
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001591747
Bitterman Kevin
C/O AKERO THERAPEUTICS, INC.
170 HARBOR WAY, 3RD FLOOR
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Stock Option (Right to Buy)
19.97
2019-11-08
4
A
0
26000
0
A
2029-11-07
Common Stock
26000
26000
D
This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019.
This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC, and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
/s/ Kevin Bitterman
2019-11-12